Glucagon-Like Peptide-1 Agonist Use in Adults With Congenital Heart Disease: Effect, Safety, and Outcomes
Authors' conclusion
GLP-1 RAs are safe and effective for weight loss in patients with ACHD with beneficial effects on glycemic control.
Study context
- Population
- Patients with adult congenital heart disease (ACHD) at Mayo Clinic (January 2013-January 2024) who were prescribed semaglutide or liraglutidepatients who received GLP-1 RA
- Participants
- Seventy patients
- Outcome
- Weight loss
- Follow-up
- Mean duration of 21 ± 20 months
Main finding
As reported in the abstract
Weight loss >5% achieved
30 (42.9%) patients
Observational data: associations, not effects.
Secondary outcomes
Moderate/severe complexity congenital heart disease (descriptive)
- Moderate/severe complexity
- 85.7%
Weight loss >5% by body mass index ≥35 kg/m² (subgroup)
- Body mass index ≥35 kg/m² vs other patients achieving weight loss >5%
- 66.7% vs 40%, P = 0.027
Weight loss by age
- Improved weight loss with younger age per 1-year age difference
- 0.17 kg (P = 0.014)
Hemoglobin A1c
- Mean lowering
- 0.6% (P = 0.054)
NYHA functional class, estimated glomerular filtration rate
- No significant changes
Safety
- Patients experiencing side effects
- One-third
- Gastrointestinal intolerance
- 20%
- Discontinued the medication due to side effects
- 11.4%
Original publication
Glucagon-Like Peptide-1 Agonist Use in Adults With Congenital Heart Disease: Effect, Safety, and Outcomes. JACC Adv. Published 24 March 2025. doi:10.
Summarised from the published abstract; every number is checked against it